Business
India’s Natco Pharma sued in US

Chennai, Sep 8
The Hyderabad based pharmaceutical major Natco Pharma Ltd on Friday said the company and others have been named as defendants in a case filed in the US.
In a regulatory filing Natco Pharma said, the company along with Celgene Corporation, Bristol Myers Squibb and Breckenridge Pharmaceutical Inc., have been named as defendants in an antitrust lawsuit in the US.
The suit was filed by Louisiana Health Service & Indemnity Company D/B/A Blue Cross and Blue Shield of Losisiana and HMO Louisiana Inc., regarding Pomalidomide (Pomalyst). Pomalidomide is a generic drug for cancer.
"Natco believes this matter is without merit. Breckenridge is the ANDA (abbreviated new drug application) holder and distribution partner for the generic product in the US," Natco said.
Meanwhile Natco Pharma's scrip that opened at Rs.917.75 on Friday went down and was changing hands at about Rs 882.

9 hours ago
H-1B Visa Fee only for new petitions, not renewals: White House

15 hours ago
Australian study unlocks secrets of ancient life through fossil faeces

15 hours ago
Nepal: Interim PM Karki has to rebuild public trust in governance

15 hours ago
Afghan senior official slams Trump's remarks on Bagram airbase

15 hours ago
Tech giants urge H-1B holders to stay in US after Trump's visa overhaul, ask those abroad to return to US

15 hours ago
CoHNA celebrates end of DOJ investigation on BAPS temple

15 hours ago
Not only US, several countries are restricting entry

15 hours ago
US decision on H-1B visa fee hike likely to have humanitarian consequences: Govt

15 hours ago
US experts warn Trump administration against undermining relationship with India: Report

18 hours ago
Our foreign policy, diplomacy have completely failed: Imran Masood slams govt after Prez Trump’s H-1B visa fee hike

18 hours ago
Congress criticises US President Trump, Centre's policies over H-1B visa fee hike

19 hours ago
Miami City Commission will open with hymns from Rig-Veda, Upanishads, Bhagavad-Gita

19 hours ago
The great American dream may now be too expensive to achieve